Hitgen Ltd., of Chengdu, China, said it entered a drug discovery research collaboration with Cambridge, Mass.-based Biogen Inc. to identify small-molecule leads for targets of interest. Hitgen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover leads, which will be licensed exclusively to Biogen. Hitgen will receive up-front payments, and be eligible for milestone payments. Specific financial details were not disclosed.